For the quarter ending 2026-03-31, WGS had -$11,073K decrease in cash & cash equivalents over the period. -$38,861K in free cash flow.
| Cash Flow | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Net loss | -63,316 | -17,666 | -7,635 | 4,280 |
| Provision for excess and obsolete inventory | - | -17 | 29 | 123 |
| Depreciation and amortization expense | 6,809 | 6,881 | 6,474 | 11,869 |
| Legal reserves | - | -4,750 | -810 | 0 |
| Stock-based compensation expense | 8,996 | 9,780 | 10,586 | 11,796 |
| Change in fair value of financial liabilities | -2,540 | -1,116 | 3,401 | -1,081 |
| Deferred tax expense | 449 | - | 246 | 202 |
| Change in third party payor reserves | -1,022 | 6,297 | -3,732 | -5,014 |
| Loss on extinguishment of debt | -6,565 | - | - | - |
| Impairment loss | 31,287 | 0 | - | - |
| Other | 1,034 | 781 | 995 | 1,387 |
| Accounts receivable | 2,558 | 13,432 | 12,910 | 9,889 |
| Inventory | -1,689 | 3,364 | -1,332 | 1,404 |
| Accounts payable and accrued expenses | -13,168 | 6,915 | -2,014 | 7,199 |
| Other assets and liabilities | 9,125 | -10,143 | -10,721 | 8,894 |
| Net cash (used in) provided by operating activities | -32,408 | -3,090 | 15,767 | 20,602 |
| Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Series Of Individually Immaterial Business Acquisitions | - | 32,856 | - | - |
| Acquisition of business, net of cash acquired and consideration on escrow paid for legacy genedx acquisition-Gene Dx | - | 0 | - | - |
| Purchases of marketable securities | 20,177 | 19,141 | 5,765 | 30,770 |
| Proceeds from sales of marketable securities | 875 | 2,062 | 0 | 0 |
| Acquisition of business, net of cash acquired | - | - | 0 | 33,195 |
| Proceeds from maturities of marketable securities | 8,500 | 10,015 | 7,250 | 26,705 |
| Purchases of property and equipment and development of internal-use software | 6,453 | 4,347 | 6,172 | 8,498 |
| Proceeds from sales of assets | - | 0 | - | - |
| Development of internal-use software assets | - | 0 | - | - |
| Proceeds from issuance of stock pursuant to employee stock purchase plan | - | 1,699 | 0 | 1,262 |
| Net cash used in investing activities | -17,255 | -11,072 | -4,687 | -45,758 |
| Proceeds from long term debt, net of issuance costs | 96,998 | 21,136 | 11,802 | 13,766 |
| Proceeds from issuance of common stock from subscription agreements | 476 | - | - | - |
| Exercise of stock options | 58 | 1,040 | 182 | 800 |
| Repayment and principal payments for long-term debt-Perceptive Term Loan Facility | 54,000 | - | - | - |
| Long-term debt principal payments | - | 305 | 304 | 602 |
| Repayment and principal payments for long-term debt-DECDLoan Agreement | 4,447 | - | - | - |
| Finance lease principal payments | 495 | 377 | 912 | 1,162 |
| Proceeds from long-term debt | - | 0 | - | - |
| Net cash provided by financing activities | 38,590 | 23,193 | 10,768 | 14,064 |
| Net (decrease) increase in cash, cash equivalents and restricted cash | -11,073 | 9,031 | 21,848 | -11,092 |
| Cash, cash equivalents and restricted cash, at beginning of period | 105,989 | 96,958 | 86,202 | - |
| Cash, cash equivalents and restricted cash, at end of period | 94,916 | 105,989 | 96,958 | - |
GeneDx Holdings Corp. (WGS)
GeneDx Holdings Corp. (WGS)